Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10709515 | 0.86 | CYP19A1 (0.55) | HSP90AA1KMT2ACYP19A1 | |
| SCHEMBL10712303 | 0.86 | HSP90AA1 (0.46) | HSP90AA1KMT2ACYP19A1CYP26A1CES2 | |
| SCHEMBL10711903 | 0.86 | CYP19A1 (0.53) | HSP90AA1KMT2ACYP19A1FAAHMGLL | |
| SCHEMBL11017338 | 0.84 | GSK3B (0.47) | HSP90AA1KMT2ACYP19A1CYP26A1CES2 | |
| SCHEMBL10361474 | 0.83 | HSP90AA1 (0.49) | HSP90AA1KMT2ACYP19A1FAAHMGLL | |
| Hydrochloric Acid SCHEMBL9792757 | 0.82 | HSP90AA1 (0.48) | HSP90AA1KMT2ACYP19A1FAAHMGLL | |
| SCHEMBL11124433 | 0.81 | CYP19A1 (0.48) | HSP90AA1KMT2ACYP19A1CYP26A1 | |
| SCHEMBL10454877 | 0.80 | CES2 (0.46) | HSP90AA1KMT2ACYP19A1FAAHMGLL | |
| SCHEMBL10709129 | 0.80 | CYP19A1 (0.41) | HSP90AA1KMT2ACYP19A1 | |
| SCHEMBL10764624 | 0.79 | CYP3A4 (0.50) | HSP90AA1KMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111217795-B | Antibacterial medicine and preparation method thereof | 华侨大学 | 2023-07-18 | — | — | CN | claimed |
| CN-111217795-A | Antibacterial medicine and preparation method thereof | 华侨大学 | 2020-06-02 | — | — | CN | claimed |
| EP-2303265-B1 | STABLE TOPICAL FORMULATION COMPRISING VORICONAZOLE | GLENMARK PHARMACEUTICALS LTD (IN) | 2014-12-10 | — | — | EP | claimed |
| US-20110105448-A1 | Stable Topical Formulation Comprising Voriconazole | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2011-05-05 | — | — | US | claimed |
| US-20060252940-A1 | CRYSTALLINE 1-[2-(2,4-DIFLUOROPHENYL)-OXIRANYL METHYL]-1H-1,2,4-TRIAZOLE | DR. REDDY'S LABORATORIES, INC. | 2006-11-09 | — | — | US | claimed |
| CN-117384136-A | NO donor type antifungal compound and preparation method and application thereof | 中国药科大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-111217795-B | Antibacterial medicine and preparation method thereof | 华侨大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-111647019-B | Triazole compound, preparation method and application thereof in antifungal drugs | 青岛大学 | 2023-02-07 | — | — | CN | disclosed |
| CN-114829354-A | Recovery method of voriconazole enantiomer | 刘杰 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021127965-A1 | METHOD FOR RECYCLING VORICONAZOLE ENANTIOMER | 刘杰 | 2021-07-01 | — | — | WO | disclosed |
| CN-111647019-A | Triazole compound, preparation method and application thereof in antifungal drugs | 青岛大学 | 2020-09-11 | — | — | CN | disclosed |
| CN-111217795-A | Antibacterial medicine and preparation method thereof | 华侨大学 | 2020-06-02 | — | — | CN | disclosed |
| EP-1231210-A2 | Azole antifungal agents, processes for the preparation thereof, and intermediates | Eisai Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
| US-5792781-A | EFFECTIVE AGAINST DERMATOMYCOSIS/VISCEROMYCOSIS CAUSED BY FUNGI, I.E., CANDIDA ALBICANS | EISAI CO., LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5789429-A | FUNGICIDE | EISAI CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5648372-A | TRIAZOLES | EISAI CO., LTD. (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0667346-A2 | Azole antifungal agents, process for the preparation there of and intermediates | Eisai Co., Ltd. (JP) | 1995-08-16 | — | — | EP | disclosed |
| EP-0174769-B1 | ANTIFUNGAL AZOLE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-11-21 | — | — | EP | disclosed |
| US-4925863-A | 1,3-DI(1,2,4-TRIAZOL-1-YL)-2-PROPANOL DERIVATIVES SUBSTITUTED WITH A STYRYL GROUP | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| EP-0174769-A1 | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252940-A1 | CRYSTALLINE 1-[2-(2,4-DIFLUOROPHENYL)-OXIRANYL METHYL]-1H-1,2,4-TRIAZOLE | CYP2F1, CYP4B1, CYP3A4 | HSP90AA1 2735/4885KMT2A 2448/4885CYP19A1 195/4885 |
| US-20110105448-A1 | Stable Topical Formulation Comprising Voriconazole | ERG28, CYP51A1, PIK3C3 | HSP90AA1 705/4885KMT2A 3269/4885CYP19A1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.